Evidence map›Paper›PMID 33316279›Full record

ArticleNeuropharmacology2021

Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.

D Matthew Walentiny, Essie Komla, Léa T Moisa, Mohammed A Mustafa, Justin L Poklis, Hamid I Akbarali, Patrick M Beardsley

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

D Matthew WalentinyDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA. Electronic address: david.walentiny@vcuhealth.org.
Essie KomlaDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA.
Léa T MoisaDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA.
Mohammed A MustafaDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA.
Justin L PoklisDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA.
Hamid I AkbaraliDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA.
Patrick M BeardsleyDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, 1217 E. Marshall Street, Richmond, VA, 23298-0613, USA; Institute for Drug and Alcohol Studies & Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, 410 N. 12th Street, PO Box 980613, Richmond, VA, 23298-0613, USA.
Virginia Commonwealth University · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI JOLENE J WINDLE · 2014 to 2026
$13.8M
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6M
Mechanisms of Ethanol's Reversal of Opioid ToleranceR01DA036975 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI AKBARALI, HAMID I, DEWEY, WILLIAM L. · 2014 to 2018
$2.3M
NIDA NIH HHS HHSN271201700008CNIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA036975NIDA NIH HHS R01 DA039942NIDA NIH HHS T32 DA007027
6 · The paper itself

Abstract

backgroundAntagonism of peripheral opioid receptors by methylnaltrexone (MNTX) was recently proposed as a potential mechanism to attenuate the development of opioid analgesic tolerance based on experiments conducted in mice. However, reports indicate that MNTX is demethylated to naltrexone (NTX) in mice, and NTX may subsequently cross the blood-brain barrier to antagonize centrally-mediated opioid effects. The goal of this study was to determine whether MNTX alters centrally-mediated behaviors elicited by the opioid analgesics, morphine and oxycodone, and to quantify concentrations of MNTX and NTX in blood and brain following their administration in mice.

methodsCombinations of MNTX and morphine were tested under acute and chronic conditions in thermal nociceptive assays. Effects of MNTX and NTX pretreatment were assessed in an oxycodone discrimination operant procedure. Blood and brain concentrations of these antagonists were quantified after their administration using liquid chromatography-mass spectrometry.

resultsMNTX dose-dependently attenuated acute and chronic morphine antinociception. MNTX and NTX dose-dependently antagonized the discriminative stimulus effects of oxycodone. MNTX and NTX were detected in both blood and brain after administration of MNTX, confirming its demethylation and demonstrating that MNTX itself can cross the blood-brain barrier.

conclusionsThese results provide converging behavioral and analytical evidence that MNTX administration in mice attenuates centrally-mediated effects produced by opioid analgesics and results in functional concentrations of MNTX and NTX in blood and brain. Collectively, these findings indicate that MNTX cannot be administered systemically in mice for making inferences that its effects are peripherally restricted.

Indexed as

Analgesics, OpioidAnimalsBlood-Brain BarrierDose-Response Relationship, DrugMaleMiceMice, Inbred C57BLMorphineNaltrexoneNarcotic AntagonistsOxycodonePain MeasurementQuaternary Ammonium CompoundsAnalgesics, OpioidmethylnaltrexoneMorphineNaltrexoneNarcotic AntagonistsOxycodoneQuaternary Ammonium CompoundsAntinociceptionMethylnaltrexoneMorphineMouseOxycodoneTolerance

Identifiers

PMID33316279
PMCPMC7887091
OpenAlexW3113232002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.